Contact
Please use this form to send email to PR contact of this press release:
Sarcomatrix Renews United States Orphan Drug Designation for LAMA2-Related Muscular Dystrophy Program
TO:
David Craig
Sarcomatrix, Inc.
+1 415-246-3311